



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/523,899

11/14/2005

Ronald Rodriguez

59562(71699)

9458

49383

7590

02/26/2009

EDWARDS ANGELL PALMER & DODGE LLP

P.O. BOX 55874

BOSTON, MA 02205

EXAMINER

LI, QIAN JANICE

ART UNIT

PAPER NUMBER

1633

MAIL DATE

DELIVERY MODE

02/26/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/523,899	Applicant(s) RODRIGUEZ ET AL.	
	Examiner Q. JANICE LI, M.D.	Art Unit 1633	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 16 December 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-22 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 1-4, 13, 15, 16 and 21 is/are allowed.
- 6) ☒ Claim(s) 14, 17, 18 and 22 is/are rejected.
- 7) ☐ Claim(s) 5-12, 19 and 20 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 04 February 2005 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The amendment and remarks filed 12/16/08 are acknowledged. Claims 14, 17 have been amended, and claims 21, 22 are newly submitted.

Election/Restrictions

In view of the allowable linking claims 1-4, 13, 15, 16, 21, the restriction requirement as to the linked inventions is hereby withdrawn, and claims 7-12 are now rejoined.

Claims 1-22 are under current examination.

Specification

The abstract of the disclosure stands objected to because it does not commence on a sheet separate from other materials of the disclosure. Correction is required. See MPEP § 608.01(b).

Claim Objections

Claim 5 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 5 describes the intended use of the vector but fails to further limit the structure of the vector.

Claims 6-12 are objected to because of the following informalities: the claims recites a chimeric protein *represented* by a nucleic acid sequence, which sequence is the coding sequence of the protein but not an amino acid sequence. Appropriate correction is required.

Claims 19 and 20 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. The claims are directed to a product, but not a process claim. The recited inactivation does not appear to further limit the structure of the vector. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 22 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 22 is vague and indefinite because of the claim limitation "site-specific". It is unclear which site it refers to and hence the metes and bounds of the claims are uncertain.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1633

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 14, 17, 18 stand rejected and claim 22 is newly rejected under 35

U.S.C. 112, first paragraph, because the specification, while being enabling for treating prostate cancer in a subject by intratumoral injection of a replication conditional adenovirus vector comprising a prostate-specific TRE operably linked to a nucleotide sequence encoding an E1A/AR chimeric protein, does not reasonably provide enablement for treating prostate cancer in a subject by administering said vector from a site remote from the tumor. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims, for reasons of record and following.

The applicant argues that the specification teaches that the vector functions in a cell-specific manner due to the TRE element.

The arguments have been fully considered but found not persuasive.

The claims are directed to a therapeutic method for treating prostate cancer. The matter at issue is whether the vectors delivered at a remote site could reach the prostate cancer in a sufficient amount such that a therapeutic effect could be achieved. The vector has to arrive at the site of the prostate cancer in a sufficient amount before they could function in a cell/tissue specific manner. To this end, although the specification prophetically contemplating various routes of administration, it fails to address the targeting hurdles known in the art. Therefore, considering the anatomic location of the prostate, in light of the state of the art as taught by the cited references of

record coupled with the guidance of the specification, the specification fails to provide sufficient evidence to establish the claimed vector indeed could reach prostate in a sufficient amount to assert a therapeutic effect.

Accordingly, for reasons of record and *supra*, the rejection stands.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The prior rejection of Claims 1-6, 13-20 under 35 U.S.C. 103(a) as being unpatentable over *Rodriguez et al* (Cancer Res 1987;57:2559-63), in view of *Suzuki et al* (Cancer Res 2001;61:1276-9) and *Becker et al* (Mole Cell Biol 1989;9:3878-87) is withdrawn in view of persuasive arguments. Particularly in light of the unpredictable nature of the interaction between AR and E1A when present individually or in the form of a fusion protein as shown in examples 1 & 2 of the specification.

Claims 1-4, 13, 15, 16, 21 are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Q. JANICE LI, M.D.** whose telephone number is **571-272-0730**. The examiner can normally be reached on 9 AM -7:00pm, Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Joseph Woitach** can be reached on **571-272-0739**. The **fax** numbers for the organization where this application or proceeding is assigned are **571-273-8300**.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Art Unit: 1633

For all other customer support, please call the USPTO Call Center (UCC) at **800-786-9199**.

/Q. JANICE LI, M.D./
Primary Examiner, Art Unit 1633

Q. JANICE LI, M.D.
Primary Examiner
Art Unit 16333

QJL

February 26, 2009